NYSE: GRDNGuardian Pharmacy Services Inc Stock
$28.55-1.01 (-3.42%)
Updated Oct 29, 2025
GRDN Price
$28.55
Fair Value Price
N/A
Market Cap
$1.81B
52 Week Low
$17.29
52 Week High
$30.39
P/E
-19.42x
P/B
10.66x
P/S
1x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.33B
Earnings
-$91.57M
Gross Margin
19.6%
Operating Margin
-5.85%
Profit Margin
-6.9%
Debt to Equity
1.04
Operating Cash Flow
$58M
Beta
0.78
Next Earnings
Nov 10, 2025
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GRDN's potential to beat the market
AStrong Buy
- Stocks with a Zen Rating of Strong Buy (A) had an average return of +32.52% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
GRDN
Ranked#10 of 42
Ranked#10 of 42
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.86 | A | |
| $15.01 | A | |
| $225.30 | A |
Be the first to know about important GRDN news, forecast changes, insider trades & much more!
GRDN News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GRDN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GRDN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GRDN is poor value based on its book value relative to its share price (10.66x), compared to the US Medical Care Facilities industry average (5.36x)
P/B vs Industry Valuation
GRDN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GRDN due diligence checks available for Premium users.
Valuation
GRDN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-19.42x
Industry
17.8x
Market
41.57x
GRDN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.66x
Industry
5.36x
GRDN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GRDN's financial health
Profit margin
Revenue
$344.3M
Net Income
$9.0M
Profit Margin
2.6%
GRDN's Earnings (EBIT) of -$77.63M... subscribe to Premium to read more.
Interest Coverage Financials
GRDN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$356.3M
Liabilities
$176.7M
Debt to equity
1.04
GRDN's short-term assets ($170.46M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRDN's short-term assets ($170.46M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRDN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$19.9M
Investing
-$13.0M
Financing
-$2.1M
GRDN's operating cash flow ($57.66M)... subscribe to Premium to read more.
Debt Coverage Financials
GRDN vs Medical Care Facility Stocks
Guardian Pharmacy Services Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.